Abstract 5568
Background
Sarcoma patients, like many other patients with rare diseases, often experience a long diagnostic trajectory, which may negatively affect their outcome in many ways. So far, research on diagnostic intervals has been retrospective. Prospective studies with large patient numbers comparing diagnostic intervals in different health care systems have not been performed. Moreover, next to survival, health-related quality of life (HRQoL) and patient satisfaction can be affected by experiencing diagnostic delay. Currently, no data are available on how the diagnostic trajectory impacts patient-reported outcomes among sarcoma patients.
Trial design
A longitudinal cohort study, QUEST, will be conducted among newly diagnosed sarcoma patients 18 years and older in one of the participating study centers in The Netherlands (five centers) or United Kingdom (3 centers). Patients will be invited before start of treatment and asked to complete questionnaires on the diagnostic pathway, risk factors (demographic, geographic, tumour characteristics etc) and patient-reported outcomes (HRQoL, social functioning, psychological distress, care satisfaction) at diagnosis and 3, 6, 12 and 24 months later. Data collection will be done within PROFILES, an established international registry for cancer patient reported outcomes. Clinical data, including vital status and tumour characteristics, will be collected from patients’ records. We aim to include 530 patients within two years, recruitment started 01-02-2018, and up till now 300patients completed baseline questionnaires (219 in NL, response rate 60%; 66 in UK, response rate 45%). Descriptive statistics will be used to quantify diagnostic intervals. The association between diagnostic interval and HRQoL, stage at diagnosis, primary treatment and survival will be explored.
Clinical trial identification
Protocol Record 2017-3881.
Editorial acknowledgement
Legal entity responsible for the study
Winette van der Graaf.
Funding
Radboudumc PROFILES registry.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5135 - Dose adjustment of chemotherapy in aggressive lymphoma using automated and standardized analysis and evaluation of DNA double strand breaks
Presenter: Julia Schröder
Session: Poster Display session 1
Resources:
Abstract
4883 - A New Population Model Validated Pharmacokinetic Similarity of HLX01 and Rituximab in B-Cell Lymphoma
Presenter: Yuankai Shi
Session: Poster Display session 1
Resources:
Abstract
4908 - Efficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma
Presenter: Sung-Nam Lim
Session: Poster Display session 1
Resources:
Abstract
2360 - Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing
Presenter: Seok Jae Huh
Session: Poster Display session 1
Resources:
Abstract
2430 - Clinical features, treatment and outcomes of colon and rectum mucosa-associated lymphoid tissue (MALT) lymphoma: Literature reviews published in English between 1993 and 2017
Presenter: Jeong Yeon Kim
Session: Poster Display session 1
Resources:
Abstract
4654 - Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 52 patients
Presenter: Guldane Cengiz Seval
Session: Poster Display session 1
Resources:
Abstract
1732 - Safety and efficacy of Bendamustine and Rituximab (BR) regimen in Indian Chronic Lymphocytic Leukemia patients
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
5784 - N-terminal B-type natriuretic peptide (NT-proBNP) as an independed prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure
Presenter: Sergey Semochkin
Session: Poster Display session 1
Resources:
Abstract
836 - The first-line effect of Bortezomib-based Therapy on Clinical Outcomes for Taiwanese Patients with multiple myeloma
Presenter: Ching-Liang Ho
Session: Poster Display session 1
Resources:
Abstract
2085 - Impact of Donor Lymphocyte Infusion in Relapsing Myeloid Neoplasms Post Allogeneic Hematopoietic Stem Cell Transplantation
Presenter: Hanafy Hafez
Session: Poster Display session 1
Resources:
Abstract